-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
INOVIO announced today that the Phase 1B clinical trial of INO-4500 (its Lassa fever DNA vaccine candidate) in Ghana has completed the first subject administration.
About INOVIO's INO-4500 Phase 1B clinical trial
INOVIO's Phase 1B clinical trial LSV-002 will recruit approximately 220 adult participants aged 18-50.
Since its establishment in 1979, the Noguchi Memorial Medical Research Institute (hereinafter referred to as the "Institute") has carried out capacity building for the prevention and control of endemic diseases and emerging and recurring diseases in Ghana and West Africa, and has become a globally recognized leading biomedicine in Africa.
About Lassa fever
Lassa fever is an animal-borne acute hemorrhagic viral disease, mainly seen in parts of West Africa.
The diagnosis of Lassa fever is difficult, there is a lack of standardized monitoring and testing, and many parts of West Africa where the outbreak occurs are usually remote, so the number of reported cases and deaths is likely to be much lower than the actual number of cases and deaths.
Note: The original text has been deleted